Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Shire, Parion join for ophthalmic drug

by Michael McCoy
May 8, 2017 | A version of this story appeared in Volume 95, Issue 19

Shire has licensed worldwide rights to P-321, a small-molecule inhibitor of the epithelial sodium channel (ENaC) being developed by Parion Sciences. P-321 is in Phase II clinical trials for dry eye disease. Inhibiting ENaC is thought to block the absorption of tears and help keep the ocular surface hydrated, the partners say. Shire will make a $20 million license payment and pay $20 million more if a near-term milestone is reached. Parion could get up to $535 million if all targets are met.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.